Skip to main content

Table 3 Treatment after the second-line chemotherapy

From: Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer

Treatment

BBP group (%)

Non-BBP group (%)

 No

16 (43.2)

17 (68.0)

 Yes (overlapping)

21 (56.8)

8 (32.0)

  TAS-102

15 (40.5)

6 (26.1)

  REGO

14 (37.8)

13 (50.0)

  CET/PANI

3 (8.1)

2 (8.7)

  Oxaliplatin-based

2 (5.4)

2 (8.7)

  Irinotecan-based

17 (45.9)

8 (34.8)

  Hepatic arterial infusion

4 (10.8)

4 (11.1)

  Others

4 (10.8)

4 (16.0)

  1. Abbreviations: BBP Bevacizumab continuation beyond progression, REGO Regorafenib, CET Cetuximab, PANI Panitumumab